Invivyd, Inc.

Welcome to the InVivid third quarter 2022 update call. I will now turn the call over to Kira Faircloth, Vice President of Government Affairs, Advocacy, and Corporate Communication.

Thank you for joining us today. Before we get started, I wanted to tend to a few housekeeping items. I invite you to review our press release and the Q3 financials included within, both of which can be found on the investor section of our website. I would like to remind you that during today's discussion, we will be making several forward-looking statements. Forward-looking statements include statements concerning, among other things, the future of the COVID-19 landscape, including the expectation of continued evolution and emergence of new variants and sub-variants, our ongoing research and clinical development plans, including the timing of said plans, technology and resources to develop therapeutic or preventative options for other infectious diseases, our expected cash runway, and other statements that are not historical fact. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements are described under the heading risk factors in our filings made with the US Securities and Exchange Commission. including our most recent quarterly report filed today. It is now my pleasure to welcome the InVivid management team to the call. I'm joined by David Herring, CEO of InVivid, Laura Walker, Chief Scientific Officer, and Fred Dristel, Interim Chief Financial Officer. With that, I'd like to turn the call over to Dave.

Good afternoon, and thanks for joining the InVivid third quarter call. It happens to be our first quarterly earnings call as a public company and my first call as Chief Executive Officer, so our agenda will be just a little different than it may be going forward. Specifically, I'd like to start by sharing my enthusiasm for InVivid in our future. Then our CSO, Laura Walker, will describe our unique capabilities, pipeline, and ongoing activities. I will then come back and talk a bit about near-term opportunities. Finally, our interim CFO, Fred Juskel, will walk you through our actual results, after which we are happy to open the line for any questions. As always, we'll be glad to follow up with analysts or investors one-on-one following this call. As you may recall, prior to joining InVivid, my role at Pfizer was the global franchise head for the mRNA portfolio. Essentially, I had the operational responsibility for the COVID vaccine in the U.S. which included worldwide production allocation and the sale of the vaccine, which is now the market-leading mRNA vaccine for the prevention of COVID-19, and future mRNA products in development. Being involved in that effort was a great privilege, given the urgency of the medical situation and the ability to make an important vaccine broadly available. At the same time, it was made clear that there would always be practical limits to the benefits a SARS-CoV-2 vaccine could provide, especially for vulnerable populations, such as the immunocompromised or other people who may not respond well to vaccination. After all, neutralizing antibody titers in response to natural SARS-CoV-2 infection wane relatively quickly, rendering all humans vulnerable to repeat infection. Over the past year, we, alongside the broader scientific community, have learned that viral evolution can challenge even the most thoughtfully discovered therapeutic and prophylactic antibodies. The past three years have seen the rise of this new human pathogen, first moving through naive human immune systems in a series of distinct dominant variants, then evolving to adapt to experienced human immune systems, and now presenting a diverse variant swarm. As coined in the public commentary, this swarm or so-called scrabble set of Omicron lineage viruses is acquiring somewhat predictable convergent mutations in the face of human immune pressure exerted by vaccination and prior infection. These convergent mutations are increasingly immune evasive relative to vaccine-induced antibody titers and increasingly challenge all prior and currently commercially available antibody therapeutics. We are pleased that to date, our candidates in late stage discovery have shown retained in vitro activity against all current and emerging variants of concern. Previously, the company attempted to meet the pre-Omicron COVID-19 challenge largely with a single molecule. The redesigned company, by contrast, has been created with a mission to meet the challenge of this bioevolution through ongoing innovation and use of our proprietary platform. Our integrated discovery platform offers us the possibility for high-potency, beneficial pharmaceutical properties and meaningful resistance to viral escape as we aim to make quality antibodies that occur at very low or zero frequency in natural human immune responses. In this way, such engineered antibodies may sit outside the pressure that drives viral escape. We as a company anticipate being able to use our platform to position ourselves for the potential obsolescence of our antibodies and believe that what is most important about InVivid is the expected productivity and efficiency of our overall discovery and development platform rather than the particulars of any one single antibody developed going forward. We believe our proprietary underlying discovery technology licensed from Atomab to be utilized in our new corporate laboratories will allow for unparalleled speed and molecular diversity in engineering. Our plan, broadly speaking, is to continue deploying our technology over the coming years as viral evolution requires and to innovate with the intent to keep pace with and indeed get ahead of COVID-19. I will ask Laura to review our recent progress and ongoing discovery and development activities.